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Objective: The purpose of this study was to determine the effect of an
intracoronary bolus injection of adenosine used in concert with ischemic
preconditioning on postischemic functional recovery and infarct size re-
duction in the rabbit heart and to compare adenosine-enhanced ischemic
preconditioning with ischemic preconditioning and magnesium-supple-
mented potassium cardioplegia. Methods: New Zealand White rabbits (n 5
36) were used for Langendorff perfusion. Control hearts were perfused at
37° C for 180 minutes; global ischemic hearts received 30 minutes of global
ischemia and 120 minutes of reperfusion; magnesium-supplemented potas-
sium cardioplegic hearts received cardioplegia 5 minutes before global
ischemia; ischemic preconditioned hearts received 5 minutes of zero-flow
global ischemia and 5 minutes of reperfusion before global ischemia;
adenosine-enhanced ischemic preconditioned hearts received a bolus injec-
tion of adenosine just before the preconditioning. To separate the effects of
adenosine from adenosine-enhanced ischemic preconditioning, a control
group received a bolus injection of adenosine 10 minutes before global
ischemia. Results: Infarct volume in global ischemic hearts was 32.9% 6
5.1% and 1.03% 6 0.3% in control hearts. The infarct volume decreased
(10.23% 6 2.6% and 7.0% 6 1.6%, respectively; p < 0.001 versus global
ischemia) in the ischemic preconditioned group and control group, but this
did not enhance postischemic functional recovery. Magnesium-supple-
mented potassium cardioplegia and adenosine-enhanced ischemic precon-
ditioning significantly decreased infarct volume (2.9% 6 0.8% and 2.8% 6
0.55%, respectively; p < 0.001 versus global ischemia, p 5 0.02 versus
ischemic preconditioning and p 5 0.05 versus control group) and signifi-
cantly enhanced postischemic functional recovery. Conclusions: Adenosine-
enhanced ischemic preconditioning is superior to ischemic preconditioning
and provides equal protection to that afforded by magnesium-supplemented
potassium cardioplegia. (J Thorac Cardiovasc Surg 1998;116:154-62)
Murry and colleagues
1 were the first to describe
an endogenous myocardial protection, ischemic
preconditioning (IPC), in which the imposition of
one or more brief periods of ischemia (3 to 5
minutes) followed by reperfusion “preconditions”
the heart in such a way that infarct size and myo-
cardial necrosis are significantly reduced during the
subsequent induction of sublethal ischemia. The
induction of endogenous myocardial protection via
preconditioning would appear to be common in all
species studied in the reduction of myocardial in-
farct volume. However, the effects of precondition-
ing on postischemic myocardial functional recovery
have been shown to vary among species in contrast
with the protection afforded by cardioplegia.2-5 In
the rat heart the use of preconditioning has been
shown to both reduce myocardial infarction and
enhance postischemic myocardial functional recov-
ery.3, 5, 6 In contrast, in the rabbit heart, although
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preconditioning has been shown to reduce myocar-
dial infarction, no enhancement of postischemic
myocardial functional recovery occurs.4, 7, 8
Downey9 has proposed that adenosine, a ubiqui-
tous biologic compound that is formed as a conse-
quence of the breakdown of high-energy phosphate
(adenosine triphosphate) during preconditioning,
plays a central role both as a mediator and as a
trigger in the cardioprotection afforded by IPC and
that continued occupancy of adenosine receptors
during ischemia is required before preconditioning
can be achieved.
Recently, it has been shown in the in vivo dog
heart that exogenous adenosine enhanced postisch-
emic myocardial functional recovery, when admin-
istered via intracoronary infusion.10 These data
agree with previous reports that indicate that there
are differential responses to steady state as com-
pared with bolus adenosine injections.11, 12 In hu-
man patients, adenosine has been shown to cause
pain and discomfort.12 Langervist and colleagues11
have shown that adenosine, when delivered by
steady-state infusion, was associated with myocar-
dial ischemia as determined by lactate production,
ST-segment depression, and chest pain. The delivery
of adenosine by intracoronary bolus injection was
found to obviate these effects.11
Using these preliminary studies as a paradigm, we
speculated that the use of an intracoronary bolus
injection of adenosine when used in concert with
IPC (adenosine-enhanced ischemic preconditioning
[APC]) may allow for enhanced myocardial protec-
tion in the rabbit heart. Our results indicate that
APC decreases myocardial infarct size and enhances
postischemic functional recovery in the rabbit heart.
In addition, our results indicate that APC is as
efficacious as magnesium-supplemented potassium
cardioplegia.
Methods
Animals and chemicals. New Zealand White rabbits
(n 5 36; 15 to 20 weeks; Millbrook Farm, Amherst, Mass.)
were housed individually and provided with laboratory
food and water as necessary. All experiments were ap-
proved by the Beth Israel Deaconess Medical Center
Animal Care and Use Committee and conformed to the
United States National Institutes of Health guidelines
regulating the care and use of laboratory animals (NIH
Publication No. 85-23, revised 1985). All chemicals used
were of electrophoresis grade or ultra-pure quality.
Langendorff perfusion. All rabbits were anesthetized
with sodium pentobarbital (Pentobarbital; Veterinary
Laboratories, Inc., Lenexa, Kan.; 100 mg/kg intrave-
nously) and heparin (200 unit/kg intravenously) via a
marginal ear vein. The heart was excised and used for
Langendorff perfusion as previously described.13, 14 The
hearts were paced via the right atrium at 180 6 3
beats/min throughout the experiment with a Medtronic
model 5330 stimulator (Medtronic, Inc., Minneapolis,
Minn.). Left ventricular systolic pressure, left ventricular
peak developed pressure, left ventricular end-diastolic
pressure, and coronary flow were continuously recorded.
Hemodynamic variables were acquired with a PO-NE-
MAH digital data acquisition system with an Acquire Plus
processor board and left ventricular pressure analysis
software (Gould, Valley View, Ohio).
Experimental protocol. Hearts were perfused for 20
minutes to establish equilibrium hemodynamics. Equilib-
rium was ceased when heart rate, coronary flow, left
ventricular pressure, and diastolic pressure were main-
tained at the same level for three continuous measure-
ment periods timed 5 minutes apart. After 20 minutes of
equilibrium perfusion, the hearts were divided into four
groups; control and global ischemia hearts received 30
minutes of equilibrium perfusion to allow for standardiza-
tion of experimental conditions. Control hearts (n 5 6)
were perfused without global ischemia at 37° C for 180
minutes. Global ischemia hearts (n 5 6) were subjected to
30 minutes of ischemia and 120 minutes of reperfusion.
Global ischemia was achieved by crossclamping of the
aorta. Magnesium-supplemented potassium (K/Mg) car-
dioplegia hearts (n 5 6) were infused with K/Mg (20
mmol/L each KCl and MgSO4) then subjected to 30
minutes of ischemia and 120 minutes of reperfusion.
Cardioplegic solution was perfused at a constant pressure
of 75 cm of water at 37° C for 5 minutes before the onset
of 30 minutes of global ischemia and 120 minutes of
reperfusion. IPC hearts (n 5 6) received 5 minutes of
zero-flow global ischemia followed by 5 minutes of reper-
fusion before 30 minutes of global ischemia and 120
minutes of reperfusion. APC hearts (n 5 6) received a 10
ml bolus injection of 1 mmol/L adenosine in Krebs buffer
(concentration determined from preliminary investiga-
tions) just before preconditioning (5 minutes of zero-flow
global ischemia followed by 5 minutes of reperfusion).
The bolus was injected into the aortic root via a sidearm
cannula located proximal to the perfusion cannula. To
separate the effects of adenosine from that of APC, a
control group (adenosine only [ADO]; n 5 6) received a
10 ml bolus injection of 1 mmol/L adenosine in Krebs buffer
10 minutes before global ischemia and reperfusion. All
hearts were paced continuously via the right atrium at 180 6
3 beats/min throughout the experiment, with a Medtronic
rapid atrial pacer (5330; Medtronic, Minneapolis, Minn.).
Rabbits were assigned randomly to treatment groups.
Comparison of wet and dry weights. Left ventricular
tissue samples (approximately 0.1 gm) from all experi-
mental groups were weighed (wet weight), dried at 80° C
for 24 hours for reweighing (dry weight), and then used
for the determination of dry/wet weight ratios, with the
use of previously described methods.13, 14
Measurement of infarct size. After reperfusion, hearts
were rapidly removed from the perfusion apparatus and
sliced across the long axis of the left ventricle, from apex
to base, into 2 mm thick transverse sections and then
incubated in 1% triphenyl tetrazolium chloride (Sigma
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Chemical Co., St. Louis, Mo.) in phosphate buffer (pH
7.4) at 38° C for 20 minutes.15 Infarct areas were en-
hanced by storage in 10% formaldehyde solution for 24
hours before final measurement.5, 15 In the global isch-
emia heart, the whole ventricle is at risk of infarction and
therefore collateral flow and estimation of the area at risk
was not required.5, 15 A copy of the stained heart slices
was traced onto a clear acetate sheet over a glass plate
under room light. The area of left ventricle and the area of
infarcted tissue were measured by an independent,
blinded observer using planimetry. The volumes of the
infarcted zone and the area at risk were calculated by
multiplying the planimetered areas by the slice thick-
ness.5, 15 Infarct volume was expressed as a percentage of
left ventricular volume for each heart.5, 15
Statistical analysis. Statistical analysis was performed
using the SAS (version 6.12) software package (SAS
Institute, Inc., Cary, N.C.). The mean 6 the standard
error of the mean for all data was calculated for all
variables. Statistical significance was determined with
repeated-measures analysis of variance with the group as
a “between subjects” factor and time as a “within subjects”
factor. Post hoc comparisons between groups for both the
average effect and at individual time points were made
with the use of a Bonferroni correction to adjust for the
multiplicity of tests. A one-way analysis of variance was
used for area of infarction.
Results
Determination of adenosine concentration used
for bolus injection. The concentration of adenosine
used for bolus injection (1 mmol/L) was determined
from preliminary investigation with adenosine con-
centrations 0.1 to 10 mmol/L. It was determined that
an adenosine concentration less than 2.5 mmol/L
but greater than 0.1 mmol/L was required as a bolus
injection with IPC to enhance postischemic func-
tional recovery (results not shown).
Equilibrium hemodynamics. No significant dif-
ferences in heart rate, left ventricular systolic pres-
sure, left ventricular end diastolic pressure
(LVEDP), left ventricular peak developed pressure
(LVPDP), positive rate of pressure rise (dP/dt), or
coronary flow were observed between or within
groups after equilibrium.
Left ventricular end-diastolic pressure. The ef-
fects of APC, IPC, and K/Mg cardioplegia on
LVEDP during equilibrium, 30 minutes of normo-
thermic global ischemia, and 120 minutes of reper-
fusion are shown in Fig. 1 and Table I. LVEDP in
APC and IPC hearts decreased to 0 mm Hg during
IPC and then returned to the control level during
the 5 minutes of reperfusion before the induction of
global ischemia. No significant difference in LVEDP
was found between groups before 30 minutes of
global ischemia (Fig. 1). The use of APC or K/Mg
cardioplegia maintained LVEDP at the control lev-
els throughout reperfusion. LVEDP after 20 min-
utes of normothermic global ischemia was signifi-
cantly increased in global ischemia and IPC hearts
as compared with control hearts (Table I). LVEDP
in ADO control hearts increased progressively dur-
ing reperfusion with maximal LVEDP being ob-
served at 120 minutes of reperfusion (180 minutes of
perfusion). Between-group comparison of LVEDP
during reperfusion (70 to 180 minutes) indicated
that there was no significant difference between the
control, ADO, K/Mg, or APC groups. A significant
difference between control versus global ischemia
(p , 0.001) and IPC (p , 0.001), ADO versus global
ischemia (p , 0.001) and IPC (p 5 0.01), K/Mg
versus global ischemia (p , 0.001) and IPC (p ,
0.001), and APC versus global ischemia (p , 0.001)
and IPC (p , 0.001) was observed.
Left ventricular peak developed pressure.
LVPDP in APC, ADO, and IPC hearts decreased to
0 mm Hg during IPC and then returned to control
levels during the 5-minute reperfusion period before
the induction of global ischemia (Fig. 2). No signif-
icant difference from control was observed between
groups before the start of global ischemia. During
the first 10 minutes of reperfusion, LVPDP in APC
hearts was significantly decreased as compared with
control (p 5 0.01) and K/Mg (p 5 0.01) hearts, but
after 20 minutes of reperfusion (80 minutes of
perfusion) no significant difference between APC,
K/Mg, and control groups was observed. However,
LVPDP in global ischemia, ADO, and IPC hearts
was significantly decreased as compared with con-
trol hearts throughout reperfusion (70 to 180 min-
utes; Table I).
Between-group comparison of LVPDP during
reperfusion (70 to 180 minutes) indicated that there
was no significant difference between control, K/Mg,
and APC groups. A significant difference between
control versus global ischemia (p , 0.001), IPC (p ,
0.001), and ADO (p 5 0.001); K/Mg versus global
ischemia (p , 0.001), IPC (p , 0.001), and ADO
(p 5 0.002); and APC versus global ischemia (p ,
0.001) and IPC (p 5 0.02) was observed. Similar
results were observed for left ventricular dP/dt (re-
sults not shown).
Coronary flow. Coronary flow in APC and IPC
hearts decreased to 0 ml/min during IPC and then
returned to the control level during the 5-minute
reperfusion period (Fig. 3). No significant difference
in coronary flow was found among groups before 30
minutes of global ischemia. No significant difference
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in coronary flow was found during reperfusion be-
tween the control, APC, and K/Mg hearts (Table I).
Coronary flow was significantly increased through-
out reperfusion (70 to 180 minutes) in global isch-
emia hearts and in ADO hearts after 60 minutes of
reperfusion (120 to 180 minutes of perfusion; Table
I). Between-group comparison of coronary flow
during reperfusion (70 to 180 minutes) indicated
that there was no significant difference between the
control, IPC, K/Mg, and APC groups. A significant
difference between control versus global ischemia
(p , 0.001) and ADO (p 5 0.01), K/Mg versus
global ischemia (p 5 0.002), and APC versus global
ischemia (p 5 0.001) was observed.
Myocardial infarct volume. A significant increase
(p , 0.001) in infarct volume expressed as a percent
of ventricular volume was observed in global isch-
emia hearts (32.9% 6 5.1%) as compared with
control hearts (1.03% 6 0.3%; Fig. 4). Infarct
volume in IPC hearts (10.23% 6 2.6%) was signif-
icantly decreased as compared with global ischemia
hearts (p , 0.001) but was significantly increased
(p 5 0.01) as compared with control hearts. In ADO
hearts, infarct volume was 7.0% 6 1.6%, which was
significantly decreased (p , 0.001) as compared with
global ischemia hearts but was not significantly
different from IPC hearts. Infarct volume was sig-
nificantly decreased to 2.9% 6 0.8% and 2.8% 6
0.55% for K/Mg and APC hearts, respectively (p ,
0.001, p 5 0.05, p 5 0.02 for K/Mg hearts as
compared to global ischemia, ADO and IPC hearts
and p , 0.001, p 5 0.05, p 5 0.02 for APC hearts as
compared with global ischemia, ADO, and IPC
hearts). No difference in infarct volume between
control, K/Mg, and APC hearts was observed. No
significant differences in dry weight/wet weight ra-
tios were found between any group.
Discussion
Previous investigation by others has shown that
IPC reduces infarct size but does not enhance
postischemic myocardial functional recovery in the
rabbit heart.4, 5, 7, 8 Although the mechanism(s) by
which IPC affords cardioprotection remain to be
Fig. 1. The effects of APC, IPC, and ADO on LVEDP during 30 minutes of global ischemia (GI) and 120
minutes of reperfusion and comparison with K/Mg cardioplegia. Results are shown as the mean and
standard error of the mean for each group (n 5 6). *Significant differences (see Table I) versus control
hearts.
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fully elucidated, a sufficient body of evidence exists
to indicate that adenosine plays a central role in this
process.9, 16-18 Several potential beneficial effects of
IPC have been ascribed to adenosine.19 Adenosine,
by its property to antagonize calcium channels, has
been shown to inhibit the sinoatrial and the atrio-
ventricular nodes and myocardial contraction,
thereby inducing cardiac arrest.20 Adenosine has
also been implicated in the protection afforded
against myocardial infarction (“second window of
protection”) observed 24 hours after the imposition
of IPC.17 In rabbit hearts it has been shown that a
5-minute infusion with adenosine followed by a
10-minute washout before ischemia reduced infarct
size from 41% to 25% as compared with 10% in
IPC-treated hearts.18 However, the transient infu-
sion of adenosine followed by washout has been
shown to be ineffectual in attenuating myocardial
stunning.7, 21
In our investigations, we have used 1 mmol/L
adenosine for bolus injection, but this concentration
may not be optimal. In preliminary experiments,
serial dilutions of adenosine (0.1 to 10 mmol/L)
were used for bolus injection. Our results indicated
that a concentration greater than 0.1 mmol/L and
less than 2.5 mmol/L was sufficient to allow for both
enhanced postischemic functional recovery and de-
creased infarct volume. No cardioprotective effects
were seen when adenosine concentration was less
than 0.1 mmol/L, although adenosine concentra-
tions of more than 2.5 mmol/L were found to induce
arrhythmia and fibrillation (results not shown).
Previous studies have suggested that enhanced
collateral flow during global ischemia would limit
the degree of ischemic injury and facilitate postisch-
emic functional recovery.22 We have used the rabbit
heart, which has no known collateral blood flow, and
we have used global ischemia, which would rule out
any supplementary coronary flow during ischemia
and which might contribute to myocardial protec-
tion. It is possible that the enhanced functional
recovery observed with APC is the result of in-
creased coronary flow during reperfusion, and this
effect cannot be excluded. Kloner and colleagues23
have previously suggested that myocyte injury oc-
curs before vascular injury, although Hearse and
colleagues24 have proposed that altered (increased)
vasoconstriction precedes and contributes to myo-
cyte injury and necrosis. Our results indicate that a
direct correlation between coronary flow and en-
hanced postischemic functional recovery is evident
but that no relationship to myocyte injury is evident.
Coronary flow in APC and K/Mg hearts returned
rapidly to the control level during reperfusion and
remained at this level throughout reperfusion and
was associated with both increased postischemic
functional recovery and decreased infarct volume.
In contrast with ADO, coronary flow in IPC and
Table I. Hemodynamic data
Group
Time (min)
70
p
Value 80
p
Value 90
p
Value 120
p
Value 150
p
Value 180
p
Value
LVPDP
(mm Hg)
Control 119.5 (5.9) 120.1 (6.0) 119.3 (5.6) 114.8 (6.1) 105.5 (7.4) 99.3 (6.8)
GI 30.8 (8.0) <0.001 40.8 (6.2) <0.001 49.6 (7.7) <0.001 47.6 (8.4) <0.001 44.0 (8.2) <0.001 42.3 (9.2) 0.001
IPC 54.8 (4.9) <0.001 59.8 (6.3) <0.001 61.1 (7.0) <0.001 63.3 (9.9) <0.001 61.8 (10.9) 0.01 59.3 (10.4) 0.04
ADO 61.3 (3.9) <0.001 79.0 (3.6) <0.001 82.1 (5.1) 0.002 75.1 (7.4) 0.01 66.8 (7.9) 0.02 56.1 (8.8) 0.02
K/Mg 99.3 (3.4) 0.15 120.1 (2.5) 1.00 126.6 (1.3) 1.00 125.1 (3.5) 1.00 115.8 (4.7) 1.00 112.6 (3.8) 1.00
APC 69.8 (2.8) <0.001 93.5 (4.8) 0.02 101.1 (6.2) 0.54 100.1 (6.1) 1.00 99.4 (6.0) 1.00 93.0 (9.4) 1.00
LVEDP
(mm Hg)
Control 4.5 (0.8) 4.5 (0.8) 4.3 (0.9) 4.8 (1.1) 6.0 (1.4) 7.0 (1.5)
GI 25.6 (5.8) 0.05 32.6 (8.4) 0.01 39.8 (6.8) <0.001 41.3 (6.8) <0.001 44.5 (7.2) <0.001 45.6 (6.1) <0.001
IPC 24.6 (8.9) 0.07 30.6 (8.6) 0.02 32.3 (6.2) <0.001 34.0 (5.2) <0.001 33.6 (5.3) 0.001 33.8 (5.3) 0.003
ADO 10.5 (3.4) 1.00 10.0 (2.9) 1.00 9.8 (2.8) 1.00 11.0 (3.1) 1.00 14.8 (4.5) 1.00 19.0 (6.4) 1.00
K/Mg 2.1 (0.6) 1.00 2.0 (0.6) 1.00 2.0 (0.6) 1.00 1.8 (0.6) 1.00 2.3 (1.0) 1.00 3.5 (1.9) 1.00
APC 3.6 (1.2) 1.00 3.0 (1.1) 1.00 2.6 (1.2) 1.00 3.8 (1.5) 1.00 5.1 (2.2) 1.00 6.0 (2.5) 1.00
Coronary
flow
(ml/min)
Control 45.0 (2.5) 43.6 (2.8) 45.5 (3.1) 45.0 (2.5) 42.8 (2.6) 42.8 (3.5)
GI 26.1 (4.0) 0.01 29.0 (3.0 0.02 27.6 (2.7) 0.002 24.0 (2.4) <0.001 20.6 (2.9) <0.001 18.0 (3.1) <0.001
IPC 39.1 (4.0) 1.00 33.5 (2.5) 0.33 32.3 (2.3) 0.05 31.5 (1.9) 0.05 29.0 (1.8) 0.06 27.8 (1.5) 0.06
ADO 36.0 (2.4) 1.00 34.8 (1.4) 0.66 34.0 (1.8) 0.13 30.3 (2.7) 0.02 24.8 (2.3) 0.004 22.5 ((2.5) 0.003
K/Mg 39.6 (4.8) 1.00 39.1 (4.5) 1.00 41.3 (4.1) 1.00 43.1 (4.0) 1.00 41.5 (4.0) 1.00 40.0 (4.4) 1.00
APC 47.1 (3.1) 1.00 44.5 (2.6) 1.00 44.6 (2.4) 1.00 43.0 (3.5) 1.00 39.0 (4.1) 1.00 36.5 (4.3) 1.00
Measurements significantly different from the control are shown in bold type. GI, Global ischemia.
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global ischemia hearts was decreased as compared
with control hearts throughout reperfusion and was
associated with decreased postischemic myocardial
functional recovery; however, infarct volume was
decreased in both IPC and ADO hearts. These
results would agree with previous reports that indi-
cated that the effects of adenosine infusion are
relatively short lived and suggest that the results
observed are associated with the additive effects of
adenosine and IPC.16, 18, 20, 25 In our model with
constant pacing, the heart rate was not altered by
adenosine infusion nor was initial coronary flow.
The effects of K/Mg cardioplegia on coronary flow
have been previously noted and may be related to
the amelioration of cytosolic calcium accumulation
during ischemia.13, 14
Mullane and colleagues26 have previously noted
that, while endogenous adenosine accumulation is
central to the cardioprotection afforded by IPC,
endogenous concentration is not sufficient to allow
for maximal cardioprotection because the adminis-
tration of exogenous adenosine or its analogs in-
creases the degree of cardioprotection. Mentzer and
colleagues16 have suggested that it is the interstitial
fluid levels of adenosine that attenuate precondi-
tioning. The mode of adenosine infusion would
appear to be of central importance in the protection
afforded by APC. Previous reports have indicated
that there are differential responses to steady state
as compared with bolus adenosine injections.11, 12
Infusion of adenosine (1 mmol/L for 5 minutes; n 5
4; results not shown) reduced infarct size to 9.1% 6
2.2% but was no more effective than ADO (p 5
0.45) or IPC (p 5 0.77) and did not enhance
postischemic functional recovery. The inability of
adenosine or IPC alone to enhance postischemic
myocardial functional recovery coincident with the
reduction of myocardial infarct size would suggest
that both the endogenous adenosine levels and
priming of adenosine receptors may be required for
cardioprotection. Our results indicate that the use of
an intracoronary bolus adenosine (1 mmol/L), by
itself, significantly decreases myocardial infarct vol-
ume in the rabbit heart but does not enhance
Fig. 2. The effects of APC, IPC, and ADO on LVPDP during 30 minutes of global ischemia (GI) and 120
minutes of reperfusion and comparison with K/Mg cardioplegia. Results are shown as the mean and
standard error of the mean for each group (n 5 6). *Significant differences (see Table I) versus control
hearts.
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postischemic myocardial functional recovery. This
would agree with a previous report27 that shows no
direct inotropic effects are associated with adeno-
sine. Although we have not determined the effect of
APC on interstitial adenosine levels, we speculate
that APC rapidly increases interstitial adenosine
levels greater than that able to be achieved by
steady-state infusion, allowing for the rapid satura-
tion of myocardial adenosine receptors, and that the
level of adenosine receptor saturation may be di-
rectly correlated with both the reduction of myocar-
dial infarct size and the degree of postischemic
functional recovery attained. Our results further
suggest that the effects of APC are cumulative in
that myocardial infarct size reduction is enhanced as
compared with either IPC or ADO alone (Fig. 4).
The exact mechanism(s), by which APC-enhanced
cardioprotection is afforded, however, will require
further investigation.
Intrinsic to the development of new myoprotec-
tive protocols for use in cardiac surgery are the
requirements of new protocols to be equal to or
better than conventional cardioplegia in providing
for enhanced postischemic functional recovery and
decreased myocardial infarct size.6 In previous stud-
ies, we have shown that the use of K/Mg cardiople-
gia significantly decreases cytosolic calcium accumu-
lation during ischemia and enhances postischemic
myocardial functional recovery in both the mature
and aged myocardium.13, 14 In this report we show
that K/Mg cardioplegia significantly enhances post-
ischemic functional recovery and decreases myocar-
dial infarct size. In addition, we show that K/Mg
cardioplegia is more effective than IPC (p , 0.001)
in reducing infarct volume. Of importance is our
finding that the use an intracoronary bolus injection
of adenosine used in concert with ischemia precon-
ditioning (APC) provides equal cardioprotection to
that afforded by K/Mg cardioplegia. Our investiga-
tions have used an isolated crystalloid buffer–per-
Fig. 3. The effects of APC, IPC, and ADO on coronary flow during 30 minutes of global ischemia (GI) and
120 minutes of reperfusion and comparison to K/Mg cardioplegia. Results are shown as the mean and
standard error of the mean for each group (n 5 6). *Significant differences (see Table I) versus control
hearts.
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fused rabbit heart model to allow for comparison
with previous reports and thus do not account for
the intervening benefits of the blood perfused
heart.1-9, 13, 14 Previous investigation, comparing
crystalloid and blood-perfused rabbit hearts, has
shown that blood-perfused hearts exhibit a greater
resistance to ischemia and a superior response to
cardioplegia as compared with crystalloid-perfused
hearts.28 Sandhu and colleagues29 have shown that
IPC is effective in reducing infarct size in both the
buffer-perfused and blood-perfused hearts but that
infarct size in buffer-perfused hearts was much
greater than in crystalloid-perfused hearts. How-
ever, it should be noted that no significant improve-
ment in postischemic function was observed with
IPC in either buffer-perfused or blood-perfused
hearts. Our results show that APC significantly
reduces myocardial infarct size and significantly
enhances postischemic functional recovery and sug-
gest that APC can be used as an alternative to
cardioplegia, affording similar levels of cardiopro-
tection.
R E F E R E N C E S
1. Murry CE, Jennings RB, Reimer KA. Preconditioning with
ischemia: a delay of lethal cell injury in ischemic myocardium.
Circulation 1986;74:1124-36.
2. Li GC, Vasquez JA, Gallagher KP, Lucchesi BR. Myocardial
protection with preconditioning. Circulation 1990;82:609-19.
3. Lasley RD, Anderson GM, Mentzer RM. Ischemic precon-
ditioning enhance postischemic recovery of function in the
rat heart. Cardiovasc Res 1993;27:565-70.
4. Cohen MV, Liu GS, Downy JM. Preconditioning causes
improved wall motion as well as smaller infarcts after tran-
sient coronary occlusion in rabbits. Circulation 1991; 84:
341-9.
5. Jenkins DP, Pugsley WB, Yellon DM. Ischemic precondi-
tioning in a model of global ischemia: infarct size limitation,
but no reduction of stunning. J Mol Cell Cardiol 1995;27:
1623-32.
6. Kolocassides KG, Galinanes M, Hearse DJ. Ischemic precon-
ditioning, cardioplegia or both? Differing approaches to
myocardial and vascular protection. J Mol Cell Cardiol
1996;28:623-34.
7. Asimakis GK, Lick SD, Conti VR. Transient ischemia cannot
precondition the rabbit heart against postischemic contractile
dysfunction. Ann Thorac Surg 1996;62:543-9.
8. Lasley RD, Noble MA, Koyn PJ, Mentzer RM Jr. Different
effects of an adenosine A1 analogue and ischemic precondi-
tioning in isolated rabbit hearts. Anal Thorac Surg 1995;60:
1698-703.
9. Downey JM. Ischemic preconditioning: natures own cardio-
protective intervention. Trends Cardiovasc Med
1992;2:170-6.
10. Randhawa MPS, Lasley RD, Mentzer RM Jr. Salutary effects
of exogenous adenosine on in vivo myocardial stunning.
J Thorac Cardiovasc Surg 1995;110:63-74.
11. Langervist B, Sylven C, Theodorsen E, Kaijser L, Helmius G,
Waldenstrom A. Adenosine induced chest pain: a compari-
son between intracoronary bolus injection and steady state
infusion. Cardiovasc Res 1992;26:810-4.
12. Sylven C, Beermann B, Jonzon B, Brandt R. Angina pectoris-
like pain provoked by intravenous adenosine in healthy
volunteers. Br Med J 1986;293:227-30.
13. Tsukube T, McCully JD, Faulk E, Federman M, LoCicero J,
Krukenkamp IB, et al. Warm magnesium cardioplegia re-
duces cytosolic and nuclear calcium and DNA fragmentation
in the senescent myocardium. Ann Thorac Surg 1994;58:
1005-11.
14. Tsukube T, McCully JD, Federman M, Krukenkamp IB,
Levitsky S. Developmental differences in cytosolic calcium
accumulation associated with surgically induced global isch-
emia: optimization of cardioplegic protection and mechanism
of action. J Thorac Cardiovasc Surg 1996;112:175-84.
15. Ytrehus K, Liu Y, Tsuchida A, Miuura T, Liu GS, Tang X-M,
et al. Rat and rabbit heart infarction: effects of anesthesia,
perfusion, risk zone, and method of infarct sizing. Am J
Physiol 1994;267:H2383-90.
16. Mentzer RM Jr, Bunger R, Lasley RD. Adenosine enhanced
preservation of myocardial function and energetics: possible
involvement of the adenosine A1 receptor system. Cardiovasc
Res 1993;27:28-35.
17. Baxter GF, Marber MS, Patel VC, Yellon DM. Adenosine
receptor involvement in a delayed phase of myocardial
protection 24 hours after ischemic preconditioning. Circula-
tion 1994;90:2993-3000.
18. Lasley RD, Koyn PJ, Hegge JO, Mentzer RM Jr. Effects of
ischemic and adenosine preconditioning on interstitial fluid
adenosine and myocardial infarct size. Am J Physiol (Heart
Circ Physiol) 1995;269:H1460-6.
Fig. 4. The effects of APC, IPC, and ADO on infarct size
during 30 minutes of global ischemia (GI) and 120
minutes of reperfusion. Results are shown as the mean
and standard error of the mean for each group (n 5 6).
*Significant differences (p , 0.001) versus global ischemia
hearts. **Significant differences for K/Mg versus ADO
(p 5 0.05) and IPC (p 5 0.02)and APC versus ADO (p 5
0.05) and IPC (p 5 0.02). There was no significant
difference in infarct size between control, K/Mg, and APC
hearts.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 116, Number 1
McCully et al. 1 6 1
19. Ely SW, Berne RM. Protective effects of adenosine in
myocardial ischemia. Circulation 1992;85:893-904.
20. Schubert T, Vetter H, Owen P, Rechart B, Opie LH.
Adenosine cardioplegia. J Thorac Cardiovasc Surg 1989;98:
1057-65.
21. Toombs CF, McGee DS, Johnston WE, Vinten-Johansen J.
Myocardial protective effects of adenosine. Circulation 1992;
86:986-94.
22. Ito BR, Libaraty DH, Engler RL. Effect of transient coronary
occlusion on coronary blood flow autoregulation, vasodila-
tory reserve and response to adenosine in the dog. J Am Coll
Cardiol 1991;18:858-67.
23. Kloner RA, Rude RE, Carlson N, Maroko PR, Deboer
LWV, Braunwald E. Ultrastructural evidence of microvascu-
lar damage and myocardial cell injury after coronary artery
occlusion. Which comes first? Circulation 1980;62:945-52.
24. Hearse DJ, Maxwell L, Saldanha C, Gavin JB. The myocar-
dial vasculature during ischemia and reperfusion: a target for
injury and protection. J Mol Cell Cardiol 1993;25:759-800.
25. Fralix TA, Murphy E, London RE, Steenbergen C. Protec-
tive effects of adenosine in the perfused rat heart: changes in
metabolism and intracellular ion homeostasis. Am J Physiol
1993;264:C986-94.
26. Mullane K, Galifianes M, Hearse DJ. Amplification of en-
dogenous adenosine by “adenosine regulating agents” a
therapeutic approach to the treatment of cardiac ischemic
syndromes. In: Abd-Elfattah AS, Wechsler AS, editors. Pu-
rines and myocardial protection. New York: Kluwer Publish-
ers; 1996. p.231-58.
27. Yao Z, Gross GJ. A comparison of adenosine induced
cardioprotection and ischemic preconditioning in dogs: effi-
cacy, time course and the role of KATP channels. Circulation
1994;89:1229-36.
28. Qiu Y, Hearse DJ. Comparison of ischemic vulnerability and
responsiveness to cardioplegic protection in crystalloid per-
fused versus blood perfused hearts. J Thorac Cardiovasc Surg
1992;103:960-8.
29. Sandhu R, Diaz RJ, Wilson G. Comparison of ischemic
preconditioning in blood perfused and buffer perfused iso-
lated heart models. Cardiovasc Res 1993;27:602-7.
Availability of Journal back issues
As a service to our subscribers, copies of back issues of The Journal of Thoracic and Cardiovascular Surgery for the preceding 5
years are maintained and are available for purchase from Mosby at a cost of $16.00 per issue until inventory is depleted. The
following quantity discounts are available: 25% off on quantities of 12 to 23, and one third off on quantities of 24 or more. Please
write to Mosby, Inc., Subscription Services, 11830 Westline Industrial Drive, St. Louis MO 63146-3318, or call 800-453-4351 or
314-453-4351 for information on availability of particular issues. If unavailable from the publisher, photocopies of complete issues
may be purchased from UMI, 300 N. Zeeb Rd., Ann Arbor, MI 48106, 313-761-4700.
The Journal of Thoracic and
Cardiovascular Surgery
July 1998
1 6 2 McCully et al.
